Novel cardiovascular biomarkers and implications for clinical trials
Valentin Fuster
This article has no abstract so we have provided the first paragraph of the full text.
Risk stratification for cardiovascular disease continues to be one of the main research focuses in 2006. Despite the excitement surrounding evolving chemical, genetic and progenitor, and imaging markers, the so-called traditional risk factors, among them obesity, sedentary lifestyle and diabetes, will probably still account for more than 90% of cardiovascular events, or so-called hard endpoints, in the next decade. Yet, the presence of traditional risk factors does not necessarily imply a cardiovascular event will occur, and not all events will imply the presence of these risk factors. Thus, can surrogate endpoints, such as biomarkers or noninvasive imaging, improve prediction of cardiovascular events?
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
